Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EarlySense Gains Patent For Respiratory Trending Analysis Designed For Reducing “Never Events”

Executive Summary

In March 2013, EarlySense Ltd. gained a US patent for the respiratory trending analysis portion of its EarlySense System, a touch-free monitoring system that detects a patient’s heart rate, respiration, and movement using a sensor placed under the bed mattress. The company is initially targeting the estimated two million medical surgical beds in US and European hospitals in hopes of improving patient safety and reducing preventable adverse events.

You may also be interested in...



“Never Events” Spur Medical Device Innovation

Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.

Recent Trends in Hemodynamic Monitoring

Growth in the hemodynamic monitoring market is being fueled by several factors, including the aging population and the increasing demand for less invasive and noninvasive technologies for measuring global parameters of oxygen delivery. While barriers to entry are high in the hemodynamic monitoring business, the prospect for future growth is significant.

New Data Position Lazertinib As Strong Contender In 1L NSCLC

Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel